Comparative Pharmacology
Head-to-head clinical analysis: CARDIOTEC versus NEPHROSCAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDIOTEC versus NEPHROSCAN.
CARDIOTEC vs NEPHROSCAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CARDIOTEC is a technetium-99m labeled tracer that binds to viable myocardial cells. Its uptake is dependent on mitochondrial membrane potential and reflects myocardial perfusion and viability. The exact mechanism involves passive diffusion across cell membranes and retention within mitochondria via interaction with the mitochondrial complex I (NADH dehydrogenase).
Calcium trisodium pentetate (NEPHROSCAN) chelates gadolinium ions by forming a stable complex with the metal, thereby reducing the toxicity and enhancing elimination of gadolinium from the body. It acts as a decorporation agent for gadolinium.
220-260 MBq (6-7 mCi) intravenously as a single dose for planar or SPECT imaging.
1 to 5 mCi (37 to 185 MBq) as a single intravenous injection for renal imaging.
None Documented
None Documented
Terminal elimination half-life is 6-8 hours; clinically, steady-state achieved in 24-32 hours
Terminal elimination half-life: 1.6 hours in normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Renal: 95% as unchanged drug via glomerular filtration; no biliary/fecal excretion.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical